Cardiff Oncology, Inc.

NASDAQ:CRDF

Biotechnology

Healthcare
$0.84 +2.12%

+$0.03 today

Market cap
$65.27M
Beta
1.38
P/E (TTM)
-1.8
EPS (TTM)
-$0.65
52W Low $1.16High $4.56

Volume 0.86M

Average 1.05M

CRDF Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Cardiff Oncology, Inc.NASDAQ: CRDF

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $6.13M rose 52.6% year over year, ahead of the +27.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 104.5% from the prior quarter. Over 3 fiscal years it compounded at +2.6% a year.

Context

  • Selling, general & admin amounted to 2398.7% of revenue in FY2025, up 571.1 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 5 analysts of $8.91M (-37.3%) for the fiscal year ending Dec 2026, a slowdown from the +14.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.13M+104.5% QoQ
Last fiscal yearDec 2025
$14.22M+14.0% YoY
LTMMar 2026
$13.02M+27.1% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+52.6%——
1 year+14.0%-37.3%-51.3 pp
3-year CAGR+2.6%-18.1%-20.6 pp
5-year CAGR+258.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
14.22M USD
Year-over-year change
+14.0%
4-year CAGR
+4.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How CRDF compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +27.1% is the highest of 9, against a peer median of -5.0%.
  • Selling, general & admin amounts to 2479.6% of revenue for CRDF, versus a peer median of 599.8%.
CRDF Competitors
Selling, General & Admin for CRDF and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$34.83M USD-4.4%-11.4%1952.5%
PEPGPepGen Inc.LTM Mar 2026$22.56M USD+1.9%+16.6%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$19.01M USD-17.8%-9.7%599.8%
MOLNMolecular Partners AGLTM Mar 2026CHF 16.11M CHF-3.8%-12.0%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$15.52M USD-5.5%-6.6%—
ELTXElicio Therapeutics, Inc.LTM Mar 2026$13.7M USD+20.3%+31.5%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$13.02M USD+27.1%+2.6%2479.6%
IPHAInnate Pharma S.A.FY2025€11M EUR-7.8%-8.7%394.7%
FBRXForte Biosciences, Inc.LTM Mar 2026$10.95M USD-28.8%+14.3%—
Peer median (excluding CRDF) —-5.0%-7.7%599.8%

Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue359K386K488K683K593K
Cost of Revenue00000
Gross Profit359K386K488K683K593K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development17.38M27.11M32.86M36.85M35.33M
Selling, General & Admin11.84M13.18M13.04M12.48M14.22M
Operating Expenses29.21M40.29M45.9M49.33M49.55M
Depreciation & Amortization451K236K398K404K904K
EBITDA(27.84M)(38.47M)(41.04M)(45.03M)(44.95M)
EBITDA Margin-7754.9%-9965.8%-8410.5%-6592.5%-7579.6%
Operating Income(28.86M)(39.9M)(45.41M)(48.65M)(48.96M)
Operating Margin-8037.6%-10337.3%-9305.7%-7123.1%-8256.3%
Interest Income264K1.58M4.07M3.26M3.1M
Interest Expense00000
Other Income / Expenses564K1.2M3.97M3.22M3.11M
Income Before Tax(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Pre-Tax Margin-7880.5%-10026.9%-8492.0%-6651.7%-7732.0%
Income Tax Expense00000
Net Income(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Net Margin-7880.5%-10026.9%-8492.0%-6651.7%-7732.0%
EPS (Basic)(0.73)(0.89)(0.93)(0.95)(0.69)
EPS (Diluted)(0.73)(0.89)(0.93)(0.95)(0.69)
Weighted Avg Shares39.03M43.6M44.68M47.65M66.84M
Weighted Avg Shares (Diluted)39.03M43.6M44.68M47.65M66.84M

Cardiff Oncology, Inc.

NASDAQ:CRDF

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.